Meloxicam Orally-Disintegrating Tablets and Metformin and sitagliptin
Determining the interaction of Meloxicam Orally-Disintegrating Tablets and Metformin and sitagliptin and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of lactic acidosis associated with the use of metformin. The precise mechanism for this interaction has not been clearly delineated. Since NSAIDs have been shown to cause a deterioration in renal function, the likelihood of lactic acidosis occurring may be increased in patients with pre-existing renal impairment. MANAGEMENT: Caution and monitoring of renal function is advised if metformin is used concomitantly with NSAIDs. Dose adjustments may be considered, particularly in patients with renal impairment. Close monitoring for the development of lactic acidosis is also recommended, particularly in patients with renal impairment. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia). References Cerner Multum, Inc. "Australian Product Information." O 0 Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Professional:MONITOR: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of lactic acidosis associated with the use of metformin. The precise mechanism for this interaction has not been clearly delineated. Since NSAIDs have been shown to cause a deterioration in renal function, the likelihood of lactic acidosis occurring may be increased in patients with pre-existing renal impairment.
MANAGEMENT: Caution and monitoring of renal function is advised if metformin is used concomitantly with NSAIDs. Dose adjustments may be considered, particularly in patients with renal impairment. Close monitoring for the development of lactic acidosis is also recommended, particularly in patients with renal impairment. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).
- Cerner Multum, Inc. "Australian Product Information." O 0
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: meloxicam
Brand name: Mobic, Vivlodex, Meloxicam Comfort Pac [DSC], Qmiiz ODT
Synonyms: Meloxicam
Generic Name: metformin / sitagliptin
Brand name: Janumet, Janumet XR
Synonyms: Sitagliptin and Metformin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Meloxicam Orally-Disintegrating Tablets-Metformin Extended-Release Tablets
- Meloxicam Orally-Disintegrating Tablets-Metformin Hydrochloride
- Meloxicam Orally-Disintegrating Tablets-Metformin Oral Solution
- Meloxicam Orally-Disintegrating Tablets-Metformin Tablets
- Meloxicam Orally-Disintegrating Tablets-Methacholine
- Meloxicam Orally-Disintegrating Tablets-Methadone
- Metformin and sitagliptin-Meloxicam Suspension
- Metformin and sitagliptin-Meloxicam Tablets
- Metformin and sitagliptin-Melphalan
- Metformin and sitagliptin-Melphalan Injection
- Metformin and sitagliptin-Melphalan Intravenous
- Metformin and sitagliptin-Melphalan oral/injection